Overview of Sales, Earnings and Financial Position
Bayer Links
Cover Picture
Very good results with Rivaroxaban
The Bayer Group’s economic success is substantially founded upon its innovative capability and long-term strategic orientation. The acquisition of Schering, Berlin, Germany, further expands the HealthCare business, and that subgroup’s research and development pipeline is well stocked, with more than 50 ongoing projects. One of these is the active ingredient rivaroxaban, currently in advanced clinical testing for the prevention and treatment of acute and chronic thrombosis. This substance achieved very good results in a recent Phase iii study. The picture shows Bayer HealthCare scientist Dr. Susanne Röhrig in the research laboratory. For further details see the news item.
Bookmark this page
E-mail this page
Advanced Search
